ProteqFlu-Te
Active substance
ATC code
Species
Horses
Indications
Active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.
Onset of immunity: 2 weeks after primary vaccination course. Duration of immunity induced by the vaccination scheme:
| - | 5 months after the primary vaccination course; |
| - | after the primary vaccination course and the booster injection 5 months later: 1 year with regard to equine influenza and 2 years with regard to tetanus. |
Dose to be administered and administration route
For intramuscular use.
For the administration of the vaccine, use sterile and antiseptic-free and/or disinfectant-free material. Shake the vaccine gently before use.
Administer one dose (1 ml), by intramuscular injection, preferably in the neck region, according to the following schedule:
| - | primary vaccination course with ProteqFlu-Te: first injection from 5–6 months of age, second injection 4-6 weeks later. |
| - |
Revaccination: o against tetanus: injection of 1 dose at an interval of maximum 2 years with ProteqFlu-Te. o against equine influenza: injection of 1 dose every year, alternatively with ProteqFlu or ProteqFlu-Te, respecting an interval of maximum 2 years for the tetanus component. |
In case of increased infection risk or insufficient colostrum intake, an additional initial injection of ProteqFlu-Te can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 5–6 months of age and 4–6 weeks later followed by revaccination).
Adverse reactions
Horses:
|
Rare (1 to 10 animals / 10,000 animals treated): |
Injection site swelling1, increased skin temperature, muscle stiffness, injection site pain |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Injection site abscess |
1 transient. usually regresses within 4 days; in rare occasions swelling can reach a diameter up to 15–20 cm, with duration up to 2–3 weeks that may require symptomatic treatment.
2 max. 1.5°C, for 1 day, exceptionally 2 days.
3 the day after vaccination.
4 which may require appropriate symptomatic treatment.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 04491/5048 |
| EAN | 3661103027409 |
